Adenocarcinoma vesical primario: nuestra experiencia

Otero, Joaquín R.; Ojeda, J.M. Duarte; Betriu, G. Cruceyra; Pérez-Martín, M.E.; Bonet, A.; Sánchez, Á. Tejido; Galvis, Ó. Leiva

doi:10.1016/s0210-4806(05)73236-8

Cited by 4 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radical cystectomy and pelvic lymph node dissection are the first choices in primary AC. However, partial cystectomy may be advantageous for mobile solitary tumors that are distant from the base (2) .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Bladder Adenocarcinoma: A Case Report

Al-Bayaty,

Abbas,

Al-saffar

et al. 2024

J. Res. Appl. Sci. Biotechnol.

View full text Add to dashboard Cite

Background: Bladder adenocarcinoma (AC) is a rare histological variant and research on the best ways to treat it is scant. Clinical Case: We present the case of a 70-year-old woman who has had hematuria for the past month with no history of serious illness. She visited a urologist, who performed a cystoscopy on her as a result. A urinary bladder adenocarcinoma was discovered in a biopsy. Complete investigations revealed no metastasis. The patient was considered for a partial cystectomy, according to the results of the MRI. She underwent the surgery, which was followed by concurrent chemo-radiotherapy. She underwent multiple reevaluations, and her case was stable after about a year of follow-up. Conclusions: With the best surgical outcomes, the choice to perform a partial cystectomy was appropriate given the tumor's location. However, a lengthy follow-up is required.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Because of intramural growth, symptoms appear later in the course of the disease, and AC is discovered at an advanced stage, which worsens the prognosis. In the early stages, only 5% of cases are diagnosed (2) . There isn't much information in the literature about how to manage it, and there are no established guidelines for care.…”

Section: Introductionmentioning

confidence: 99%

Bladder Adenocarcinoma: A Case Report

Al-Bayaty,

Abbas,

Al-saffar

et al. 2024

J. Res. Appl. Sci. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…Patients with urachal cancer often present with advanced disease that cannot be treated with surgery; up to 20-30% of patients present with regional or distant metastasis with subsequent poor survival outcomes [16]. For this reason, and because there is no consensus on the treatment, patients with urachal cancer usually have a poor prognosis for all stages [8,17,18] and the 5-year overall survival (OS) rate for patients with urachal adenocarcinoma is 27-61% [19,20,21,22,23]. …”

Section: Introductionmentioning

confidence: 99%

Treatment Outcome and Relevance of Palliative Chemotherapy in Urachal Cancer

Jung¹,

Sun²,

Park³

et al. 2014

Chemotherapy

View full text Add to dashboard Cite

Background: Urachal cancer is a rare malignancy that accounts for <1% of bladder cancers. There is currently no consensus on the diagnosis and management of urachal cancer and there are very few reports on palliative chemotherapy for unresectable disease. We delineate the clinical features and treatment outcome of urachal cancer, in particular the relevance of palliative chemotherapy in recurrent, metastatic disease. Methods: The clinicopathologic variables and treatment outcome of patients who were treated for urachal cancer were retrospectively reviewed. Results: Among 28 eligible patients, 25 had localized disease and 3 had metastatic disease at initial diagnosis. All patients with localized disease underwent curative resection and there was disease recurrence in 10. Out of 13 patients with metastatic disease either at initial diagnosis or during follow-up, the lung was the most common metastatic site (n = 5), followed by the liver, bone and peritoneum. Ten patients received palliative chemotherapy. A total of 24 chemotherapeutic regimens were administered; regimens with a base of fluoropyrimidine (5-FU), taxane and gemcitabine were the most common. The overall response rate of all chemotherapeutic regimens was 16.7%. The 5-FU-based regimens showed a good response, with 2 of 4 patients who received these showing a partial response. One tumor with a partial small-cell component showed a partial response to both an etoposide-based regimen and a taxane-based regimen. Conclusions: In urachal cancer, curative surgery is still the recommended treatment with respect to overall survival. A 5-FU-based chemotherapy regimen could be considered for metastatic recurrent disease. © 2014 S. Karger AG, Basel

show abstract

Case Report: Bladder adenocarcinoma: primary or urachal?

et al. 2019

View full text Add to dashboard Cite

Background: Bladder adenocarcinoma (AC) is a scarce histological variant and there are few studies on its proper management. No previous case reports present the management of a urachal tumor and the incidental finding of bladder adenocarcinoma. Clinical case: We present the case of a young woman with nonspecific symptoms, who presented with a prior history of dysuria, bladder tenesmus, suprapubic pain and urinary urgency for one year, which had been treated as recurrent urinary tract infection. A partial cystectomy plus extended lymphadenectomy was scheduled. We found a bladder tumor with characteristics of a urachal tumor and the pathological report indicated a primary bladder AC. The patient had a complete recovery at one year of follow-up. Conclusions: A patient can present with a tumor with urachal characteristics; however, the pathology report can show primary AC. The decision to perform partial cystectomy was an appropriate option for the location of this tumor, with optimal surgical results. Still, a long-term follow-up is necessary. More specific management guidelines are required for the treatment of AC.

show abstract

Adenocarcinoma vesical primario: nuestra experiencia

Cited by 4 publications

References 9 publications

Bladder Adenocarcinoma: A Case Report

Bladder Adenocarcinoma: A Case Report

Treatment Outcome and Relevance of Palliative Chemotherapy in Urachal Cancer

Case Report: Bladder adenocarcinoma: primary or urachal?

Contact Info

Product

Resources

About